

婦人科(3) 外来化学療法

疾患群別の外来化学療法室病床利用数

	R5	R4	R3	R2	R1	H30	H29	H28	H27	H26	H25	H24	H23	H22	H21
外来化学療法室病床利用数	536	503	602	557	501	349	330	226	289	472	356	293	358	214	312
施行症例数	95	101	83	89	105	78	67	51	70	104	72	65	81	54	63
子宮頸癌・腔癌・外陰癌	28	33	24	24	29	25	20	13	18	30	17	26	21	16	22
子宮体癌・肉腫・GTN	36	39	26	32	34	24	24	19	23	30	18	17	29	17	14
卵巣癌・卵管癌・腹膜癌	31	29	33	33	42	29	23	19	29	44	37	22	31	21	27

レジメン別の外来化学療法室病床利用数

レジメン	R5	R4	R3	R2	R1	H30	H29	H28	H27	H26	H25	H24	H23	H22	H21
TC	47	67	119	89	99	48	39	85	115	168	151	155	195	118	146
TC+Bev	5	12	9	39	44	50	41	9	0	0	0	0	0	0	0
dd-TC	0	0	0	0	0	0	2	0	0	10	2	0	0	0	0
DC	38	38	39	54	58	24	33	37	32	51	34	29	50	36	45
weekly-PTX	9	12	35	21	36	75	29	31	62	123	97	37	67	18	74
weekly-PTX+Bev	0	0	1	0	0	0	46	25	0	0	0	0	0	0	0
PLD	34	28	32	39	27	43	25	22	40	57	41	9	35	21	11
PLD+Bev	1	25	18	12	5	10	4	0	0	0	0	0	0	0	0
GEM	37	5	17	21	13	4	7	3	12	22	5	26	0	0	0
GEM+Bev	0	0	0	0	2	3	5	0	0	0	0	0	0	0	0
Irinotecan	10	4	9	7	0	3	5	0	7	16	5	37	9	19	32
Irinotecan+Bev	0	0	0	30	5	0	0	0	0	0	0	0	0	0	0
CN	1	24	49	2	0	15	1	0	0	19	21	0	0	0	0
SOX	0	2	2	0	0	0	0	4	9	6	0	0	0	0	0
CapeOX	0	1	4	0	0	0	0	0	0	0	0	0	0	0	0
Bev	0	16	43	101	135	41	32	0	3	0	0	0	0	0	0
GD	0	0	0	0	13	17	13	9	3	0	0	0	0	0	0
ADM	2	0	1	3	1	1	4	0	0	0	0	0	0	0	0
Eribulin	0	4	8	12	10	13	28	1	0	0	0	0	0	0	0
MTX	42	19	72	37	24	0	16	0	4	0	0	0	0	0	0
ACT-D	0	0	25	0	0	0	0	0	0	0	0	0	0	0	0
BEP	0	3	0	5	2	0	0	0	2	0	0	0	0	0	0
EMA/CO	4	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Carboplatin	2	0	0	0	0	2	0	0	0	0	0	0	0	0	0
PLD+Carboplatin	1	3	1	0	1	0	0	0	0	0	0	0	0	0	0
Docetaxel	0	0	3	5	0	0	0	0	0	0	0	0	0	0	0
PAOLA	4	20	4	0	0	0	0	0	0	0	0	0	0	0	0
TP-CCRT	0	16	21	0	0	0	0	0	0	0	0	0	0	0	0
Pembrolizumab	194	95	44	59	25	0	0	0	0	0	0	0	0	0	0
Lenvatinib+Pembrolizumab	26	39	13	0	0	0	0	0	0	0	0	0	0	0	0
TC+Bev+Pembrolizumab	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TC+Pembrolizumab	14	8	0	0	0	0	0	0	0	0	0	0	0	0	0
Carboplatin+Pembrolizumab	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PTX+Pembrolizumab	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cemiplimab	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0
【治験】CALLA CCRT+Durvalumab/placebo	0	3	24	20	0	0	0	0	0	0	0	0	0	0	0
【治験】B21 TC+Pembrolizumab/placebo	1	13	5	0	0	0	0	0	0	0	0	0	0	0	0
【治験】A18 CCRT+Pembrolizumab/placebo	29	23	0	0	0	0	0	0	0	0	0	0	0	0	0
【治験】DUO-E TC+Durvalumab/placebo+Olaparib/placebo	13	18	3	0	0	0	0	0	0	0	0	0	0	0	0
【治験】Bintrafusp alfa	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
【治験】SGNTV-003 Tisotumab Vedotin/chemo	0	5	0	0	0	0	0	0	0	0	0	0	0	0	0
その他	0	0	1	0	0	0	0	0	0	0	0	0	2	2	4